rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Novacyt de volgende biotech raket!

70.915 Posts
Pagina: «« 1 ... 1196 1197 1198 1199 1200 ... 3546 »» | Laatste | Omlaag ↓
  3. [verwijderd] 26 juli 2020 09:14

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Dit ziet er wel uit als een interessant bericht.

    40.000 devices die ze aanschaffen. Wat was hier de prijs van?
    280.000 test per dag a 40 euro per stuk al denk ik dat dit per set is van 10-14 stuks. Daarnaast zorgt dit er wel direct voor dat de oude tests minimaal gebruikt zullen worden.
  6. [verwijderd] 26 juli 2020 09:26

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Louis7 schreef op 26 juli 2020 09:20:

    [...]
    Welke link, deze?
    finance.yahoo.com/amphtml/news /france-expands-free-covid-19-222451052.html?guccounter=1&guce_referrer=aHR0cHM6Ly90LmNvL0FhbHl3ck5BYUc_YW1wPTE&guce_referrer_sig=AQAAAIgVlcmrgHb-iHj68K5XqKjVbYJzzsjOxioyMtIdTywR2UCPsrOp_KxOdVLKSPo3EWZOzGDNkVAa4xA9H8b0DdEE2fXByu9b_jllXWaLrDfwBJplJI1mUMq7dl8ww6n3NgEJWthSZL2iofI1oRdfYs4G8QZleODety956M02rSsX&__twitter_impression=true
    Doet het nu wel inderdaad. Ziet er veelbelovend uit! AB
  8. forum rang 6 trab33 26 juli 2020 18:13

    • trab33

      Lid sinds: 30 sep 2003

      Laatste bezoek: 09 mrt 2025

    • Aanbevelingen

      Ontvangen: 3677

      Gegeven: 1005

    •    Aantal posts: 11.348

    quote:
    Louis7 schreef op 22 juli 2020 17:39:

    novacyt.com/2020/07/22/2000-patient-c...

    2,000 patient clinical trial using Novacyt's near-patient testing system initiated in London care homes

    Paris, France and Camberley, UK - 22 July 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, notes the initiation of a clinical trial by Queen Mary University of London using the Company's innovative near-patient testing system. The study is investigating whether daily COVID-19 testing reduces the infection rate, morbidity and mortality in the high-risk care home population.

    The randomised clinical trial, recruiting up to 2,000 residents in 50 care homes across east London, is being led by Professor Jo Martin, President of the Royal College of Pathologists and Professor of Pathology at Queen Mary University of London. The study is using a mobile or near-patient testing (NPT) system for COVID-19 developed by Novacyt (further detail below), which comprises the Company's COVID-19 polymerase chain reaction (PCR) test, direct-to-PCR RNA extraction kit (exsig™ Direct), and portable testing instruments (Q16 and Q32 instruments), to ensure reliable results are received within an hour of testing.

    The clinical trial team comprises researchers, medical students and laboratory experts from Queen Mary and Novacyt. Daily testing, using Novacyt's NPT system, is being trialled for residents, staff and visitors in 25 care homes. As the comparator, the other 25 care homes will receive standard central laboratory testing once a week.

    As part of the clinical trial, the effectiveness of mid-nose nasal swabs compared to invasive nasopharyngeal swabs will be evaluated to support ease of use, lower levels of discomfort and demonstrate more reproducible data.

    Professor Jo Martin, Professor of Pathology at Queen Mary University of London, and lead investigator of the study, commented:

    "This work has the potential to bring a new rapid COVID-19 testing system to those at highest risk and help interrupt community transmission. If found to be successful in care homes, it could be very useful in a wide range of settings, helping to make a quick diagnosis and keep an environment free of COVID-19.

    "With rapid daily testing, we can report back to the care home on the same day, so that they can take action to reduce transmission in their care home and prevent outbreaks into the wider community. By undertaking this study in the diverse East London community, we're hoping to protect one of the most vulnerable groups in the UK, and the frontline staff who are caring for them."

    Graham Mullis, Group CEO of Novacyt, added:

    "We are delighted to be working with Professor Jo Martin and her expert team at Queen Mary University of London to complete this important clinical trial. We believe daily testing with our near-patient testing system, which incorporates the use of our market leading COVID-19 test, has the potential to reduce the transmission of SARS-CoV-2 in the high-risk care home population and in a wider community setting. We believe our new system increases the number of options available for rapid and reliable COVID-19 testing outside of centralised care and we expect to launch the system by the end of July 2020."

    Novacyt's near-patient testing system

    The Company's first COVID-19 test was designed for professional, central laboratory use only. In this format, the components of the test are supplied in specific vials which laboratory staff are required to pipette, along with the patient sample, in precise volumes, into the reaction vessel. Whilst this is customary in clinical diagnostic laboratories, for decentralised near-patient testing (NPT) settings a more direct procedure is required.

    Novacyt's objective is therefore to develop a system with a reduced number of workflow steps for NPT. The Company plans to use its expertise in PCR testing to coat and stabilise the essential biological components required for its COVID-19 test onto laboratory products, such as reaction tubes. As a result, the laboratory products will be "ready-to-use" on Novacyt's q16 and q32 portable instruments and will only require the addition of a small amount of patient sample to initiate the COVID-19 test.

    Also part of the NPT system is the Company's recently developed direct-to-PCR extraction kit (exsig™ Direct), which extracts RNA from patient samples and further reduces the number of workflow steps. As a result, the NPT system is ideally suited to applications in mobile settings, such as care homes, key hospital departments and other community locations. The Company expects to launch its NPT system by the end of July 2020.

    ze hebben zelfs vandaag (zondag) info verzameld in de rusthuizen
    zouden ze dan toch nog morgenochtend met bericht komen ?
    twitter.com/JoMartin_path/status/1287...

    vooral het antwoord lijkt mij bemoedigend
    Jo thanks once again for being at the forefront of research of such significant benefit
  13. TheBiG 27 juli 2020 08:07

    • TheBiG

      Lid sinds: 16 jan 2020

      Laatste bezoek: 07 mrt 2025

    • Aanbevelingen

      Ontvangen: 147

      Gegeven: 15

    •    Aantal posts: 306

    Novacyt S.A. ("Novacyt", the "Company" or the “Group”): R&D Update

    R&D highlights

    Launch of near-patient (mobile) testing, which comprises Novacyt’s COVID-19 test, direct-to-PCR RNA extraction kit (Exsig™ Direct), and q16 and q32 instruments

    Launch of a saliva sampling type to support ease of patient sampling, lower levels of discomfort and demonstrate more reproducible data

    Development of a respiratory testing panel to diagnose and distinguish between influenza A&B, RSV and COVID-19. Launch expected during September 2020 for the 2020/21 flu season in the Northern hemisphere

    Development of a two-gene test to address markets employing this testing approach. Launch expected no later than September 2020

    Development, together with a partner, of a serology (antibody) test to detect past infection of COVID-19. Launch expected in Q4 2020

    quote:

    TheBiG schreef op 27 juli 2020 08:06:

    www.voxmarkets.co.uk/rns/announcement...
  14. forum rang 10 voda 27 juli 2020 08:18

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 09 mrt 2025

    • Aanbevelingen

      Ontvangen: 93538

      Gegeven: 22917

    •    Aantal posts: 384.577

    Goed nieuws weer. Ze blijven aan de weg timmeren! Wanneer vliegt die koers nu eens OMHOOG? AB.
  15. [verwijderd] 27 juli 2020 08:32

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    RNS: novacyt.com/wp-content/uploads/2020/0...

    Graham Mullis, Group CEO of Novacyt, commented:
    “Novacyt has established itself as a pioneer in COVID-19 diagnostics through the rapid development and success of its PCR test for the virus. We remain committed to building on this innovative position for COVID-19 testing, and more broadly across infectious diseases, as we continue to invest in the business to address unmet needs in the diagnostics market. The immediate pipeline of new products is expected to drive incremental revenue for the Company in the near-term, but Novacyt’s strengthened financial position also means we are able to redefine our R&D pipeline for the next three years, which we expect to drive significant and continued growth opportunities in the longer-term.”
    This announcement c
  16. forum rang 10 voda 27 juli 2020 08:36

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 09 mrt 2025

    • Aanbevelingen

      Ontvangen: 93538

      Gegeven: 22917

    •    Aantal posts: 384.577

    Het nieuws begint "door te sijpelen"...

    Theor. open 3,10 08:35:46
  21. forum rang 6 trab33 27 juli 2020 09:15

    • trab33

      Lid sinds: 30 sep 2003

      Laatste bezoek: 09 mrt 2025

    • Aanbevelingen

      Ontvangen: 3677

      Gegeven: 1005

    •    Aantal posts: 11.348

    wat staat er in het persbericht?
    ze hebben nu al cash genoeg om 3 jaar verder te ontwikkelen op nieuwe producten en dat de nieuwe producten de cash gaat aanzwengelen maar ook als je zo tussen de lijnen doorleest zie ik binnen een paar maanden een kleine overname gebeuren
    Ze zijn goed bezig ,laat ze maar verkoopcijfers brengen
70.915 Posts
Pagina: «« 1 ... 1196 1197 1198 1199 1200 ... 3546 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.097
AB InBev 2 5.525
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.867
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.772
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.764
Aedifica 3 923
Aegon 3.258 322.961
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.896
Agfa-Gevaert 14 2.051
Ahold 3.538 74.343
Air France - KLM 1.025 35.220
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.046
Alfen 16 25.021
Allfunds Group 4 1.510
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.503
AMG 971 134.010
AMS 3 73
Amsterdam Commodities 305 6.735
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.027
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.787
Arcelor Mittal 2.034 320.848
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.333
Aroundtown SA 1 220
Arrowhead Research 5 9.747
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.445
ASML 1.766 108.747
ASR Nederland 21 4.502
ATAI Life Sciences 1 7
Atenor Group 1 521
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.690
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.412